Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient.
OBJECTIVE
The case of a patient who developed thrombosis after receiving a single dose of romiplostim is reported.


CONCLUSIONS
A 63-year-old, 76-kg Caucasian man arrived at our clinic complaining of right-lower-extremity edema and redness. The patient had a complicated cardiac history, including two coronary artery bypass grafts and five percutaneous coronary interventions. The patient had a history of stage IV marginal zone lymphoma of the distal stomach and proximal duodenum and stage IV mantle cell lymphoma, both of which were successfully treated. He also underwent peripheral blood autologous bone marrow transplantation. Over a year later, the patient was found to have profound thrombocytopenia, with a platelet count of <5 × 10(9)/L. A bone marrow biopsy was negative for active lymphoma but suggested idiopathic thrombocytopenia purpura (ITP). One week after receiving a single subcutaneous dose (1 μg/kg) of romiplostim, the patient complained of lower-right-extremity edema and redness. Suspicion of a deep vein thrombosis (DVT) was confirmed with a Doppler study. At the time of his DVT, his platelet count was 51 × 10(9)/L. The patient was given enoxaparin 1 mg/kg subcutaneously twice daily for six months. Romiplostim was discontinued after the first dose; however, the patient continues to take danazol. Since then, the patient's platelet count has consistently remained above 50 × 10(9)/L. The patient had no further venous thromboembolic events.


CONCLUSIONS
A 63-year-old man with a history of cardiovascular disease and prior malignancy developed a DVT after receiving a single dose of romiplostim for the treatment of ITP.
Department of Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Eugene
E
Przespo
Anjana
A
Elefante
D016026:Bone Marrow Transplantation / Q000379:methods; D003613:Danazol / Q000627:therapeutic use; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013926:Thrombopoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000175:diagnosis
D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim; D003613:Danazol